| From pharmaceuticals to nutraceuticals: bridging disease prevention and management |
59 |
| Proton pump inhibitors: use and misuse in the clinical setting |
24 |
| A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients |
20 |
| PD-1/PD-L1 pathway inhibitors in advanced prostate cancer |
19 |
| Dupilumab for treatment of atopic dermatitis |
17 |
| Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews |
16 |
| Treatment and prevention of HIV infection with long-acting antiretrovirals |
15 |
| LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature |
15 |
| Clinical and pharmacological profile of benznidazole for treatment of Chagas disease |
14 |
| Treatment of sarcoidosis: grading the evidence |
14 |
| Multidrug resistance in Helicobacter pylori: current state and future directions |
14 |
| A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults |
13 |
| Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria |
13 |
| Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients |
13 |
| The role of the placenta in drug transport and fetal drug exposure |
12 |
| The pharmacological management of metabolic syndrome |
12 |
| Psychopharmacological advances in eating disorders |
11 |
| The role of pharmacogenomics in adverse drug reactions |
11 |
| A viewpoint on rational and irrational fixed-drug combinations |
11 |
| Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen |
10 |
| Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia |
10 |
| A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone |
10 |
| Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations |
10 |
| Pharmacological management of late-onset hypogonadism |
9 |
| The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs |
9 |
| Role of genetic testing in patients undergoing percutaneous coronary intervention |
9 |
| Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura |
8 |
| A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone |
8 |
| Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies |
8 |
| Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights |
8 |
| Continuous flow technology vs. the batch-by-batch approach to produce pharmaceutical compounds |
8 |
| Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis |
8 |
| The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors |
8 |
| Novel developments of hepatitis B: treatment goals, agents and monitoring tools |
8 |
| Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis |
7 |
| Antibiotic exposure at the site of infection: principles and assessment of tissue penetration |
7 |
| Pharmacology and pharmacokinetics of imatinib in pediatric patients |
7 |
| Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis |
7 |
| Overview of precision oncology trials: challenges and opportunities |
7 |
| PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma |
7 |
| Clinical pharmacology of old age |
7 |
| Fremanezumab for the preventive treatment of migraine in adults |
7 |
| Carbamazepine adverse drug reactions |
7 |
| On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements |
7 |
| Novel immunotherapeutic approaches for hepatocellular carcinoma treatment |
7 |
| Statins and the potential for higher diabetes mellitus risk |
6 |
| Role of rivaroxaban in the prevention of atherosclerotic events |
6 |
| Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation |
6 |
| Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma |
6 |
| Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients |
6 |
